Priscilla K Stumpf1, Ellen D Yorke2, Issam El Naqa3, Kyle C Cuneo4, Jimm Grimm5, Karyn A Goodman6. 1. Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, Colorado. Electronic address: priscilla.stumpf@cuanschutz.edu. 2. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida. 4. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 5. Department of Radiation Oncology, Geisinger Health System, Danville, Pennsylvania; Department of Medical Imaging and Radiation Sciences, Thomas Jefferson University, Philadelphia, Pennsylvania. 6. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
PURPOSE: Stereotactic body radiation therapy (SBRT) in the management of adrenal metastases is emerging as a well-tolerated, effective method of treatment for patients with limited metastatic disease. SBRT planning and treatment utilization are widely variable, and publications report heterogeneous radiation dose fractionation schemes and treatment outcomes. The objective of this analysis was to review the current literature on SBRT for adrenal metastases and to develop treatment guidelines and a model for tumor control probability of SBRT for adrenal metastases based on these publications. METHODS AND MATERIALS: A literature search of all studies on SBRT for adrenal metastases published from 2008 to 2017 was performed, and outcomes in these studies were reviewed. Local control (LC) rates were fit to a statistically significant Poisson model using maximum likelihood estimation techniques. RESULTS: One-year LC greater than 95% was achieved at an approximated biological equivalent dose with α/β = 10 Gy of 116.4 Gy. CONCLUSIONS: While respecting normal tissue tolerances, tumor doses greater than or equal to a biological equivalent dose with α/β = 10 Gy of 116.4 Gy are recommended to achieve high LC. Further studies following unified reporting standards are needed for more robust prediction. Published by Elsevier Inc.
PURPOSE: Stereotactic body radiation therapy (SBRT) in the management of adrenal metastases is emerging as a well-tolerated, effective method of treatment for patients with limited metastatic disease. SBRT planning and treatment utilization are widely variable, and publications report heterogeneous radiation dose fractionation schemes and treatment outcomes. The objective of this analysis was to review the current literature on SBRT for adrenal metastases and to develop treatment guidelines and a model for tumor control probability of SBRT for adrenal metastases based on these publications. METHODS AND MATERIALS: A literature search of all studies on SBRT for adrenal metastases published from 2008 to 2017 was performed, and outcomes in these studies were reviewed. Local control (LC) rates were fit to a statistically significant Poisson model using maximum likelihood estimation techniques. RESULTS: One-year LC greater than 95% was achieved at an approximated biological equivalent dose with α/β = 10 Gy of 116.4 Gy. CONCLUSIONS: While respecting normal tissue tolerances, tumor doses greater than or equal to a biological equivalent dose with α/β = 10 Gy of 116.4 Gy are recommended to achieve high LC. Further studies following unified reporting standards are needed for more robust prediction. Published by Elsevier Inc.
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Felix Ehret; David Kaul; Markus Kufeld; Clara Vom Endt; Volker Budach; Carolin Senger; Christoph Fürweger; Alfred Haidenberger; Alexander Muacevic Journal: J Cancer Res Clin Oncol Date: 2022-03-15 Impact factor: 4.553